Dr Neal Shore speaks to ecancer about the post hoc analysis of the phase three EMBARK trial.

This study evaluated whether patients with high-risk biochemical recurrence of prostate cancer could maintain disease control after stopping therapy.

The results showed that patients treated with enzalutamide plus leuprolide were more likely to sustain prostate-specific antigen levels below 0.2 nanograms per milliliter for up to three years after treatment suspension compared with either therapy alone.

Notably, about 1 in 25 patients receiving combination therapy maintained low prostate-specific antigen levels alongside recovery of normal testosterone levels, suggesting the possibility of durable treatment-free remission.

These findings highlight the long-term benefit of combination therapy over monotherapy approaches.